Which future for circulating microRNAs as biomarkers of acute myocardial infarction?

Goretti, Emeline; Devaux, Yvan

doi:10.21037/atm.2016.11.21

Cited by 5 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the use of miR-19a in different types of MI may act more effectively than traditional tests for patients with few symptoms at early stages of MI for strict diagnostic approaches. Therefore, predictive biomarkers for the development of targeted therapies and novel therapeutic methods for early diagnosis of AMI should be identified (Goretti and Devaux, 2016).…”

Section: Discussionmentioning

confidence: 99%

“…CTn I and other laboratory tests are considered as the acceptable routine tests in clinical settings by cardiologists for accurate diagnosis, however these test are associated with several limitations (Fichtlscherer et al, 2011). The level of CTn I can be increased 8 h after MI and it also can be raised in the liver and end-stage renal diseases, which results in a delay in diagnosis and affects the effective treatment (Li et al, 2014;Goretti and Devaux, 2016). Accordingly, these tests have no specificity and also are poor predictors.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Molecular miR-19a in Acute Myocardial Infarction: Novel Potential Indicators of Prognosis and Early Diagnosis

Mansouri

Mohammadzad

2020

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Objective: Due to the increasing annual incidence rate of disability and mortality in patients with acute myocardial infarction (AMI), the need for an appropriate diagnostic tool has become a crucial urgent issue. An increase in biomarkers and protein levels in response to AMI can be used as a predictive biomarker with different sensitivities and specificities. This study aimed at investigating the role of miR-19a as a biomarker with acceptable sensitivity and specificity for early diagnosis of AMI. Methods: We studied 175 patients with AMI admitted within 12 h of symptom onset and 90 healthy subjects as control group. Patients were divided into two groups, including group I (normal vessels and no significant artery stenosis) and primary percutaneous coronary intervention (PCI) group II (patients with more than 50% stenosis in vessels and severe atherosclerosis) diagnosed by angiography. The expression level of miR-19a was evaluated by the real-time polymerase chain reaction and other serum chemistries were also analyzed. Results: The results demonstrated that circulating miR-19a levels were significantly increased in patient groups compared to the control group (2.88 ± 1.06 vs. 5.93 ± 1.28, P<0.0001). We also found that miR-19a levels were higher in group II (134.62-fold) than group I (15.42-fold). The upper levels of miR-19a were significantly correlated with the increased serum levels of CK-MB (ρ=0.29, P<0.0001), CTn I (ρ=0.4, P<0.0001) and creatinine (ρ=0.27, P<0.0001). In addition, Receiver Operating Characteristic (ROC) analysis revealed that circulating miR-19a had considerable diagnostic accuracy for the patients with normal vessel with an AUC of 0.930 (95% CI: 0.697-0.765) and for PCI patients with an AUC of 0.966 (95% CI: 0.748-0.784). Conclusion: Circulating miR-19a possibly has prognostic value to be used as a promising molecular target for early diagnosis and prognosis of AMI.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Molecular miR-19a in Acute Myocardial Infarction: Novel Potential Indicators of Prognosis and Early Diagnosis

Mansouri

Mohammadzad

2020

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

show abstract

“…More efforts have focused on miRNAs in cancer as they were first observed in cancer cell lines [83,84,85,86,87] and so far “liquid biopsy” was conceived as a way to make a complete profiling of a cancer disease from a drop of blood [88,89,90]. More recent evidence widens the applicability of miRNAs as biomarker also for other diseases [91,92,93].…”

Section: Microgels and Hydrogel Microparticles In Multiplex Assaysmentioning

confidence: 99%

Bioengineering Microgels and Hydrogel Microparticles for Sensing Biomolecular Targets

Battista

Causa

Netti

2017

Gels

View full text Add to dashboard Cite

Hydrogels, and in particular microgels, are playing an increasingly important role in a diverse range of applications due to their hydrophilic, biocompatible, and highly flexible chemical characteristics. On this basis, solution-like environment, non-fouling nature, easy probe accessibility and target diffusion, effective inclusion of reporting moieties can be achieved, making them ideal substrates for bio-sensing applications. In fact, hydrogels are already successfully used in immunoassays as well as sensitive nucleic acid assays, also enabling hydrogel-based suspension arrays. In this review, we discuss key parameters of hydrogels in the form of micron-sized particles to be used in sensing applications, paying attention to the protein and oligonucleotides (i.e., miRNAs) targets as most representative kind of biomarkers.

show abstract

“…29, 30 These findings, however, have yet to be translated to the clinical setting, and the majority of studies have so far failed to show superiority of miRNA-based biomarkers over traditional risk factors such as troponin. 31 Additionally, miRNAs exhibit impressively pleiotropic effects, impacting expression of multiple genes in a variety of tissues, posing the challenge of specificity for any potential therapies. Even more interestingly, miRNAs (specifically miR33a/b) play a role in interactions between three genes that have previously emerged on methylome-wide screens for plasma lipids ( CPT1A , ABCG1 , and SREBF1 ), 27 illustrating the necessity of analytic approaches that integrate across –omics layers for a fuller understanding of complex traits.…”

mentioning

confidence: 99%

The State of Cardiovascular Genomics: Abundant Data, Limited Information

Aslibekyan

Ruiz-Narváez

2017

Revista Española de Cardiología (English Edition)

View full text Add to dashboard Cite

Which future for circulating microRNAs as biomarkers of acute myocardial infarction?

Cited by 5 publications

References 12 publications

Molecular miR-19a in Acute Myocardial Infarction: Novel Potential Indicators of Prognosis and Early Diagnosis

Molecular miR-19a in Acute Myocardial Infarction: Novel Potential Indicators of Prognosis and Early Diagnosis

Bioengineering Microgels and Hydrogel Microparticles for Sensing Biomolecular Targets

The State of Cardiovascular Genomics: Abundant Data, Limited Information

Contact Info

Product

Resources

About